Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms
Journal of Diabesity · 11.09.2025 · 1 (1)
DOI: 10.66381/jod.2025.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabesity, online erschienen am 11.09.2025. Verfasst von Fareha Rasheed und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Linaclotide (Linzess) is a guanylate cyclase-C agonist used for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). While clinical trials support its effectiveness and safety, real-world data from patients remain essential for understanding long-term outcomes, discontinuation causes, and withdrawal experiences.
Objective
To assess the effectiveness of Linaclotide use, reasons for discontinuation, and post-discontinuation symptoms through a patient-reported survey.
Methods
An online survey (social media) was conducted with 86 respondents who had used linaclotide. Questions focused on duration of use, reason for prescription, symptom improvement, causes of discontinuation, and post-discontinuation gastrointestinal and systemic symptoms.
Results
Among 86 respondents, 48% used linaclotide for less than three months and 37% for more than six months. The primary indication was constipation (71%) followed by irritable bowel syndrome (29%). Complete symptom resolution was reported by 35% of patients, while 47% had partial improvement and 18% reported no benefit. Discontinuation was common, with 49% stopping due to side effects and 29% due to cost or insurance issues. After discontinuation, abdominal pain (46%) and constipation (34%) were the most frequent gastrointestinal symptoms, whereas systemic withdrawal-like symptoms included headache (24%), anxiety or depression (24%), fatigue (20%), and sweating (12%).
Conclusion
While many patients experience some benefit from linaclotide, side effects, affordability, and symptom recurrence after discontinuation remain challenges. Post-discontinuation withdrawal-like symptoms may occur and warrant clinical recognition and management. Keywords: Linaclotide; constipation; IBS-C; side effects; Linzess
Zitieren
APA
Rasheed, F., Jamil, M. A., Kanwal, S., Ullah, S., Liaquat, B., & Shah, J. (2025). Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms. Journal of Diabesity, 1(1). https://doi.org/10.66381/jod.2025.002
Vancouver
Rasheed F, Jamil MA, Kanwal S, Ullah S, Liaquat B, Shah J. Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms. Journal of Diabesity. 2025;1(1). doi:10.66381/jod.2025.002
BibTeX
@article{Rasheed2025,
author = {Rasheed, Fareha and Jamil, Muhammad Azhar and Kanwal, Saira and Ullah, Sibghat and Liaquat, Bushra and Shah, Junaid},
title = {Real-World Patient Experience with Linzess (Linaclotide): Efficacy, Discontinuation, and Withdrawal Symptoms},
journal = {Journal of Diabesity},
year = {2025},
volume = {1},
number = {1},
doi = {10.66381/jod.2025.002}
}
EUVIMED